NCT03058029Unknown不适用
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Assessing the Effect of Gelesis200 on Body Weight in Overweight and Obese Subjects Without or With Type 2 Diabetes
适应症
试验速览
- 阶段
- 不适用
- 入组人数
- 300
- 试验地点
- 60
- 主要终点
- Proportion of subjects with weight loss ≥5.0%
研究概览
简要总结
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Assessing the Effect of Gelesis200 on Body Weight in Overweight and Obese Subjects without or with Type 2 Diabetes
详细描述
Multicenter, two-cohort, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose, adaptive (Two Phases).
In the first Phase of the adaptive design, unblinded interim analyses were conducted on 57 subjects and used to adjust the design for the second Phase. The first Phase was completed under protocol Version 1.0. Data used in the unblinded interim analyses of the first Phase will not be included in the second Phase (protocol Version 2.0 and subsequent protocol versions) analyses.
The study will evaluate the safety, tolerability and efficacy of Gelesis200 as a superabsorbent hydrogel for weight loss in treated diabetic subjects, untreated diabetic subjects, and prediabetic subjects (Cohort 1).
The study will evaluate separately the safety, tolerability and efficacy of Gelesis200 for weight loss in normoglycemic subjects (Cohort 2).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 22 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female
- •Age ≥22 years and ≤65 years
- •BMI ≥27 kg/M2 and ≤40 kg/M2
- •Non-diabetic subjects, including:
- •Normoglycemic subjects with FPG <100 mg/dL [<5.6 mmol/L] at both Screening Visits with HbA1c <5.7% (<39 mmol/mol), or
- •Prediabetic subjects with FPG ≥100 mg/dL and <126 mg/dL (≥5.6 mmol/L and ≤7.0 mmol/L) at both Screening Visits with HbA1c ≤6.4% (≤46 mmol/mol) [if only one (1) value is within this range, the other value should not be ≥126 mg/dL (≥7.0 mmol/L) and HbA1c should be ≥5.7% (≥39 mmol/mol) and ≤6.4% (≤46 mmol/mol)]; or Diabetic subjects, including:
- •Untreated subjects with FPG ≤200 mg/dL (≤11.2 mmol/L) at both Screening Visits and either FPG ≥126 mg/dL (≥7.0 mmol/L) at both Screening Visits or FPG <126 mg/dL (<7.0 mmol/L) at one (1) or both Screening Visits with HbA1c ≥6.5% (≥48 mmol/mol), or
- •Drug-treated subjects with metformin and/or DPP-4 inhibitors with FPG ≥70 mg/dL and ≤270 mg/dL (≥3.9 mmol/L and ≤15.1 mmol/L) at both Screening Visits
- •Ability to follow verbal and written instructions
- •Consent obtained via signed ICF
排除标准
- •Pregnancy (or positive serum or urine pregnancy test(s) in females of childbearing potential)
- •Absence of medically approved contraception in females of childbearing potential (e.g., hysterectomy, oral contraceptive medications, intrauterine device combined with a barrier method, two (2) combined barrier methods such as diaphragm and condom or spermicide, or condom and spermicide; bilateral tubal ligation and vasectomy are acceptable contraceptive methods when combined with a single method above)
- •History of allergic reaction to CMC, citric acid, sodium stearyl fumarate, maltodextrin, gelatin, or titanium dioxide
- •Participation in a weight loss study within the past six (6) months
- •Administration of GSP2, GSP3, Gelesis100, or Gelesis200 in a previous study
- •Administration of investigational products within one (1) month prior to Screening Visit 1
- •Blood transfusion within three (3) months prior to Screening Visit 1
- •Smoking cessation within six (6) months prior to Screening Visit 1 or considering smoking cessation during the study
- •Anticipated surgical intervention during the study period
- •Known Type 1 Diabetes
- •History of eating disorders including binge eating (except mild binge eating) or emesis ≥2/week from any cause within six (6) months prior to Screening Visit 1
- •Weight change ≥3% within three (3) months prior to and during the Screening period
- •Supine SBP >160 mm Hg and/or supine DBP >95 mm Hg
- •Angina, coronary bypass, or myocardial infarction within six (6) months prior to Screening Visit 1
- •History of swallowing disorders within six (6) months prior to Screening Visit 1
- •Esophageal anatomic abnormalities (e.g., webs, diverticuli, rings)
- •History of gastric or duodenal ulcer within six (6) months prior to Screening Visit 1
- •History of gastroparesis (e.g., chronic nausea, vomiting ≥2 occurrences per week, heartburn, etc.) within six (6) months prior to Screening Visit 1
- •History of gastric bypass or any other gastric surgery
- •History of inflammatory bowel diseases
- •History of intestinal stricture (e.g., Crohn's disease)
- •History of intestinal obstruction or high risk of intestinal obstruction, including suspected small bowel adhesions
- •History of pancreatitis within six (6) months prior to Screening Visit 1
- •History of malabsorption within six (6) months prior to Screening Visit 1
- •Laxative users, except those on stable doses within one (1) month prior to Screening Visit 1
- •History of hepatitis B or C within six (6) months prior to Screening Visit 1
- •History of HIV
- •History of cancer within the past five (5) years (except adequately-treated localized basal cell skin cancer or in situ uterine cervical cancer)
- •Any other clinically significant disease interfering with the assessments of Gelesis200 (e.g., disease requiring corrective treatment, potentially leading to study discontinuation)
- •Abnormal serum TSH
- •HbA1c >8.5% (>69 mmol/mol)
- •Serum LDL cholesterol ≥160 mg/dL (≥4.15 mmol/L)
- •Serum triglycerides ≥350 mg/dL (≥3.96 mmol/L)
- •Positive test for drugs of abuse in the urine
- •Any relevant biochemical abnormality interfering with the assessments of Gelesis200
- •Anti-obesity medications (including herbal preparations) within one (1) month prior to Screening Visit 1
- •Systemic corticosteroids within one (1) month prior to Screening Visit 1
- •Thyroid hormones or preparations within one (1) month prior to Screening Visit 1 [except stable dose of replacement therapy for at least two (2) months]
- •TSH suppression therapy for thyroid cancer
- •Estrogen within one (1) month prior to Screening Visit 1 [except stable dose of replacement therapy or contraceptives for at least one (1) month]
- •Any other medication known to cause weight loss or weight gain within one (1) month prior to Screening Visit 1
- •Antidiabetic medications within one (1) month prior to Screening Visit 1 [except stable doses of metformin and DPP-4 inhibitors for at least one (1) month in subjects with Type 2 Diabetes]
- •Change in medications treating hypertension within one (1) month [one (1) week for diuretics] prior to Screening Visit 1
- •Change in medications treating dyslipidemia within one (1) month prior to Screening Visit 1
- •Anticipated requirement for use of prohibited concomitant medications
- •Any other condition that, in the opinion of the Investigator or Sponsor, would interfere with the subject's ability to participate in the study
结局指标
主要结局
Proportion of subjects with weight loss ≥5.0%
时间窗: Change from baseline to day 171 (week 25)
In treated diabetic subjects, untreated diabetic subjects, and pre-diabetic subjects (Cohort 1)
Percent change in body weight
时间窗: Change from baseline to day 171 (week 25)
In treated diabetic subjects, untreated diabetic subjects, and pre-diabetic subjects (Cohort 1)
次要结局
- Percent change in FSI(Up to 25 weeks)
- Proportion of subjects with weight loss ≥5.0%(Up to 25 weeks)
- Change in HbA1c(Up to 25 weeks)
- Percent change in insulin AUC during OGTT(Up to 25 weeks)
- Proportion of subjects with weight loss ≥10.0%(Up to 25 weeks)
研究者
研究点 (60)
Loading locations...
相似试验
招募中
不适用
Clinical Study to Evaluate the Effect of Different Doses of UC-II® Supplementation on the Range of Motion & Joint Discomfort in Healthy SubjectsJoint PainNCT05212259Vedic Lifesciences Pvt. Ltd.375
已完成
2 期
A Trial Investigating the Effect of 4 Weeks Dosing of XEN-D0501 on Blood Glucose Reduction in Patients With DiabetesEfficacySafetyPharmacokineticsDiabetes Mellitus, Type 2NCT05353686Pila Pharma54
已完成
2 期
A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of TD-1211 in Subjects With Opioid-Induced ConstipationOpioid Induced ConstipationNCT01459926Glycyx Therapeutics217
已完成
不适用
Investigating the Efficacy of Brain Octane® Oil on Cognition, Coordination, Reaction Time and Measurements of Physical Performance in Recreationally Active AdultsHealthyNCT04095728Bulletproof 360, Inc.30
已完成
不适用
Study to Assess Effects of Postbiotic vs Placebo in Participants With Diarrhea-predominant IBSDiarrhea-Predominant Irritable Bowel SyndromeNCT06346847A-Mansia Biotech S.A.384